[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 904-911

  Kalkanis, Dimitrios ^a   Stefanovic, Alexandra ^a   Paes, Fabio ^a   Escalon, Maricer P ^a   Serafini, Aldo ^a   Lossos, Izidore S ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

FDG PET CT; Lung toxicity; Lymphoma; Pneumonitis; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AWARENESS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG DISEASES; LYMPHOMA, NON-HODGKIN; MALE; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68449088165     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902919200     Document Type: Article

References (33)

1. Maloney DG, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol 2002;29:2-9.
2. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003;22: 7359-7368.
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
4. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
5. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001;42:1329-1337.
6. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximabinduced acute pulmonary fibrosis. Mayo Clin Proc 2004;79: 949,953.
7. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-104.
8. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690-2691; discussion 2690-2691.
9. Montero AJ, McCarthy JJ, Chen G, Rice L. Acute respiratory distress syndrome after rituximab infusion. Int J Hematol 2005;82:324-326.
10. Soubrier M, Jeannin G, Kemeny JL, Tournadre A, Caillot N, Caillaud D, et al. Organizing pneumonia after rituximab therapy: Two cases. Joint Bone Spine 2008;75:362-365.
11. Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004;80:164-167.
12. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004;45:2321-2325.
13. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005;81:169-170.
14. Ghesquieres H. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005;16:1399.
15. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-919.
16. Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature. Leuk Lymphoma 2006;47:1683-1685.
17. Kim KM, Kim HC, Jeon KN, Kim HG, Kang JH, Hahm JR, et al. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 2008;49:155-158.
18. Macartney C, Burke E, Elborn S, Magee N, Noone P, Gleadhill I, et al. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following RCHOP and pegylated filgrastim. Leuk Lymphoma 2005;46: 1523-1526.
19. Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin C Jr, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: Phase II trial. Clin Lymphoma 2003;4:36-42.
20. Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 2006;24:234-237.
21. Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, Naparstek E. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006;6: 407-409.
22. Nieuwenhuizen L, Verzijlbergen FJ, Wiltink E, Grutters JC, Biesma DH. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximabinduced pneumonitis in patients with non-Hodgkin's lymphoma. Haematologica 2008;93:1267-1269.
23. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007;25:571-578.
24. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996;154:1851-1856.
25. Lee Y, Kyung SY, Choi SJ, Bang SM, Jeong SH, Shin DB, et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006;21:183-186.
26. Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: Evaluation with positron emission tomography. Respiration 2006;73:197-202.
27. Tateishi U, Hasegawa T, Seki K, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organising pneumonia: Semi-quantitative evaluation using computed tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:906-912.
28. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med 2008;22:111-114.
29. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximabcontaining regimens. Ann Oncol 2009;20:309-318.
30. Moskowitz C, Hamlin HP, Hoewitz SM, Noy A, O'Connor OA, Palomba ML, et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood (ASH Annual Meeting Abstracts) 2006;108:161a.
31. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224.
32. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the sideeffects of rituximab treatment. Br J Haematol 2001;115:807-811.
33. Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2:378-384.